Tom Sellig

 connected with Tom Sellig, CEO, Adare Pharma Solutions, to discuss manufacturing investment trends, 3D-printed tablets, FDA dynamics, and the workforce strategies shaping the company's growth.

Tom Sellig on CDMO Innovation and US Manufacturing Growth

PharmTech: What Technologies Are Most Central to Adare's Innovation Strategy?

 Patient-centric dosage forms are core to our model, and 3D printing of tablets is one of the most exciting areas driving our growth. The technology allows us to differentiate product formulations and produce a wide range of dosage forms and release profiles in ways that more conventional manufacturing approaches cannot easily match. We're also paying close attention to the ongoing conversation around solubility and bioavailability enhancement. While it's an important capability to have, we think many companies are still working within the boundaries of existing technologies. We're developing what we believe are novel solutions that could leapfrog some of what's currently available in the market.

How Are Shifts at the FDA Affecting Your Development Timelines?

The FDA is going through significant changes right now, and that's creating a genuinely different dynamic between CDMOs [contract development and manufacturing organizations] and pharma companies. The conversation is increasingly about how to accelerate timelines while still working within the regulatory framework. We're actively supporting products that have received priority review vouchers, and that creates real pressure to move faster. It's a challenge, but it's also an opportunity for us to demonstrate the value of a CDMO that has the technical depth to execute under that kind of pressure.

How Is Adare Approaching Talent Acquisition and Retention?

Talent is a critical priority for us. We have an internal acquisition team, but we're also building something we call the Adare Academy, a structured, skills-based development and training program for all employees. It covers both soft skills and hard skills, including science and technology, with an explicit focus on career development pathways. The goal is not just to attract people, but to retain them. Lower turnover translates directly into continuity for our teams, for our client relationships, and ultimately for service quality.

How Do You View the Wave of Reshoring Commitments from Large Pharma, and What Does It Mean for CDMOs?

The scale of investment being discussed is significant. That said, these are long-horizon projects. Whether all of them come to fruition, and on what timeline, remains to be seen. Our response is to focus on what we can act on today: building out selective capacity and capabilities that position us to support the industry's growth as those investments materialize. We don't need to wait for the full wave, we need to be ready when it arrives.

Articles

Adare Pharma Solutions is prioritizing patient-centric dosage forms, with 3D-printed tablets enabling differentiated formulations and tailored release profiles beyond conventional manufacturing. The company is also pursuing next-generation solubility and bioavailability approaches intended to surpass current market options. FDA operational shifts are intensifying sponsor–CDMO collaboration around accelerated development, particularly for programs leveraging priority review vouchers. Growth plans emphasize workforce stability via a structured internal training and career-pathway platform. Reshoring commitments are viewed as meaningful but long-cycle, driving selective near-term capacity buildout.

Tom Sellig, Adare, discusses 3D-printed tablets, US reshoring investment, FDA timeline pressures, and workforce development strategies driving CDMO growth.

Q&A: Tom Sellig on Why Complex Formulations Are Driving CDMO Growth

Tom Sellig, Adare Pharma Solutions, shares how the CDMO is positioning for growth amid U.S. reshoring and oral dose innovation trends.

, Tom Sellig, CEO, Adare Pharma Solutions, spoke with 

 to offer his perspective on the forces shaping pharmaceutical development and manufacturing today, from advanced dosage form technologies to the regulatory environment and the industry's reshoring momentum.

Sellig sees the current wave of foreign investment into US manufacturing as a meaningful opportunity for contract development and manufacturing organizations (CDMOs). He says, “as we see companies looking to try to invest in the United States, the opportunity for us is to support these complex formulations that are driving patient needs throughout the world today.”

On the innovation front, Sellig highlights 3D printing of tablets as a consequential growth drivers, enabling differentiated formulation profiles and a broader range of release mechanisms. He also points to solubility and bioavailability enhancement as a crowded but evolving space, suggesting Adare is developing proprietary approaches that could outpace currently available technologies.

Sellig also touches on regulatory dynamics, noting that ongoing changes at the FDA are reshaping how CDMOs and pharma companies collaborate. With priority review vouchers, for example, the agency is placing real pressure on development timelines and demanding faster paths to market.

Workforce development is also an important theme of the discussion as Sellig touches on the launch of the "Adare Academy," an internal training initiative covering both scientific hard skills and professional soft skills, designed to reduce turnover and strengthen client service continuity.

On the broader reshoring narrative, Sellig acknowledges the scale of commitments being made, close to $500 billion pledged by large pharma, while remaining pragmatic. "We're focusing on what we can do today, building out selective capacity and capabilities in order to support the industry's requirements and needs of growth," he says.

Foreign investment and reshoring efforts are creating near-term openings for CDMOs to support increasingly complex formulation work in the United States. Advanced dosage-form innovation is accelerating, with 3D-printed tablets positioned to expand release profiles and product differentiation, while solubility and bioavailability enhancement remains competitive but technically dynamic. Regulatory shifts at FDA are compressing development timelines, with mechanisms such as priority review vouchers intensifying speed-to-market expectations and collaboration demands. Workforce capability is being reinforced through structured internal training to improve retention and ensure continuity in client-facing execution.

Tom Sellig, Adare Pharma Solutions, shares how the CDMO is positioning for growth amid US reshoring and oral dose innovation trends.